News

Collaborators at the Keio and Osaka Universities Present Key Non-Clinical Data with Stable/Functional-Induced Regulatory T Cells (S/F-iTregs) in Autoimmune Disease Models USA – English USA – English

by

OSAKA, Japan, May 29, 2023 /PRNewswire/ — RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting. Their presentation demonstrated that in a murine pemphigus model, S/F-iTregs significantly decreased clinical scores, circulating anti-Dsg3 IgG titers, and other autoimmune markers related to Pemphigus. Collaborators also reported that S/F-iTregs generated … Read more

Aromatherapy Expert Michael Hulbert Unveils New Book “Practical Aromatherapy for Everyday Living”

by

Self Care and Well Being Just Got a Delightful Information Boost HARTLAND, Mich., May 28, 2023 /PRNewswire/ — Aromatherapy designer Michael Hulbert, who, with his wife Anna, crafted over 30 best-selling aromatherapy blends in the last decade, announces the release of his comprehensive new book and guide, “Practical Aromatherapy for Everyday Living.” “Practical Aromatherapy for … Read more

Concord Coalition Welcomes Compromise Agreement Between President Biden and House Speaker Kevin McCarthy; Urges Debt Limit Reform

by

WASHINGTON, May 28, 2023 /PRNewswire/ — The Concord Coalition said today that the budget and debt limit agreement reached by President Biden and Speaker McCarthy is a sound compromise that can be enacted in time to prevent any default on the federal government’s legal obligations.  Concord Coalition executive director Robert L. Bixby stated: “As with any … Read more

77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

by

SHANGHAI, May 28, 2023 /PRNewswire/ — Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter) today announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor (“TGCT”), will be released at the 2023 American Society of Clinical Oncology (“ASCO”) annual meeting to be … Read more

Le groupe Menarini partage de nouvelles analyses de l’étude clinique EMERALD d’ORSERDU® (élacestrant) dans le cancer du sein métastatique à l’ASCO 2023 USA – English USA – Deutsch Latin America – español France – Français Brazil – Português

by

·  ORSERDU (élacestrant) a été approuvé par la FDA en janvier 2023 pour le traitement du cancer du sein avancé ou métastatique à récepteurs d’œstrogènes (ER) positifs et à récepteurs 2 du facteur de croissance épidermique humain (HER2) négatifs avec des mutations ESR1 (ESR1-mut) qui se trouvent dans jusqu’à 40 % des tumeurs ·  Chez les patientes dont … Read more

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

by

TORONTO, May 27, 2023 /PRNewswire/ – Cora Therapeutics, a dynamic life sciences startup based in Toronto, proudly unveils the results of a clinical trial at the Canadian Association of Interventional Radiologists (CAIR) annual meeting in Quebec City. Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary … Read more

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options

by

NEW YORK, May 27, 2023 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Chinook Therapeutics, Inc. (“Chinook” or the “Company”) (NASDAQ: KDNY). If you suffered losses exceeding $50,000 investing in Chinook stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner … Read more

En el marco de la ASCO 2023, Menarini Group comparte su nuevo análisis del estudio clínico EMERALD de ORSERDU® (Elacestrant) para el cáncer de mama metastásico Latin America – español USA – English USA – English USA – Deutsch Brazil – Português

by

ORSERDU (elacestrant) fue aprobado por la Administración de Alimentos y Medicamentos (FDA) en enero de 2023 para el cáncer de mama avanzado o metastásico positivo al receptor de estrógeno (ER) y negativo al factor de crecimiento epidérmico humano 2 (HER2) con mutaciones en ESR1 (ESR1 -mut) que se encuentran en hasta el 40 % de … Read more

Nuvaxovid™ von Novavax erhält positive CHMP-Stellungnahme für vollständige Marktzulassung zur Prävention von COVID in der EU

by

GAITHERSBURG, Maryland, 27. Mai 2023 /PRNewswire/ — Novavax, Inc. Nasdaq: NVAX), ein globales Unternehmen, das Impfstoffe auf Proteinbasis mit seinem neuartigen Matrix-M™-Adjuvans entwickelt, gab heute bekannt, dass Nuvaxovid™ (NVX-CoV2373) in der Europäischen Union (EU) nach einer positiven Stellungnahme der European Medicines Agency für Medicinal Products for Human Use (CHMP) zur vollständigen Zulassung als Erstimpfung bei Personen … Read more

UHC offers to trade GI prior auth for a poorly defined alternative

by

NORTH BETHESDA, Md. and BETHESDA, Md. and DOWNERS GROVE, Ill., May 26, 2023 /PRNewswire/ — After weeks of being questioned by patients and GI providers about a new prior authorization policy planned to go into effect June 1, UnitedHealthcare requested a meeting today with the American College of Gastroenterology, American Gastroenterological Association and American Society … Read more